About Procollagen C-endopeptidase enhancer 1
Procollagen C-endopeptidase enhancer 1 (PCOLCE) is a protein
from Homo sapiens identified by UniProt accession
Q15113, 449 residues long.
MolForge cross-references it against 0 known binders and
127 disease associations.
Target properties
| Protein name | Procollagen C-endopeptidase enhancer 1 |
| UniProt accession | Q15113 |
| Gene | PCOLCE |
| Organism | Homo sapiens |
| Length | 449 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (127)
Diseases linked to this target (Open Targets).
- breast adenocarcinoma · score 0.24
- hemoglobin measurement · score 0.23
- erythrocyte count · score 0.22
- cutaneous melanoma · score 0.18
- head and neck squamous cell carcinoma · score 0.11
- endometrial cancer · score 0.09
- neoplasm · score 0.08
- mean corpuscular volume · score 0.07
- mean platelet volume · score 0.07
- non-alcoholic steatohepatitis · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q15113-F1 | alphafold | PREDICTED | 79.57 | — |
Amino-acid sequence (449 residues)
MLPAATASLL GPLLTACALL PFAQGQTPNY TRPVFLCGGD VKGESGYVAS EGFPNLYPPN KECIWTITVP EGQTVSLSFR VFDLELHPAC RYDALEVFAG SGTSGQRLGR FCGTFRPAPL VAPGNQVTLR MTTDEGTGGR GFLLWYSGRA TSGTEHQFCG GRLEKAQGTL TTPNWPESDY PPGISCSWHI IAPPDQVIAL TFEKFDLEPD TYCRYDSVSV FNGAVSDDSR RLGKFCGDAV PGSISSEGNE LLVQFVSDLS VTADGFSASY KTLPRGTAKE GQGPGPKRGT EPKVKLPPKS QPPEKTEESP SAPDAPTCPK QCRRTGTLQS NFCASSLVVT ATVKSMVREP GEGLAVTVSL IGAYKTGGLD LPSPPTGASL KFYVPCKQCP PMKKGVSYLL MGQVEENRGP VLPPESFVVL HRPNQDQILT NLSKRKCPSQ PVRAAASQD
Explore Procollagen C-endopeptidase enhancer 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets